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Abstract
Background: Risk estimation of gastrointestinal stromal tumours (GIST) is based on tumour size and mitotic rate
according to the National Institutes of Health consensus classification. The indication for adjuvant treatment of
patients with high risk GIST after R0 resection with small molecule inhibitors is still a controversial issue, since these
patients represent a highly heterogeneous population. Therefore, additional prognostic indicators are needed. Here,
we evaluated the prognostic value of cyclin H expression in GIST.
Methods: In order to identify prognostic factors of GIST we evaluated a single centre cohort of ninety-five GIST
patients. First, GISTs were classified with regard to tumour size, mitotic rate and localisation according to the NIH
consensus and to three additional suggested risk classifications. Second, Cyclin H expression was analysed.
Results: Of ninety-five patients with GIST (53 female/42 male; median age: 66.78a; range 17-94a) risk classification
revealed: 42% high risk, 20% intermediate risk, 23% low risk and 15% very low risk GIST. In patients with high risk
GIST, the expression of cyclin H was highly predictive for reduced disease-specific survival (p = 0.038). A
combination of cyclin H expression level and high risk classification yielded the strongest prognostic indicator for
disease-specific and disease-free survival (p ≤ 0.001). Moreover, in patients with tumour recurrence and/or
metastases, cyclin H positivity was significantly associated with reduced disease-specific survival (p = 0.016)
regardless of risk-classification.
Conclusion: Our data suggest that, in addition to high risk classification, cyclin H expression might be an indicator
for “very-high risk” GIST.
Background
Gastrointestinal stromal tumours (GIST) display a wide
range of clinical and pathological features and represent
the largest group of mesenchymal tumours of the gas-
trointestinal tract. They are mostly characterised by
a gain-of function mutation of the c-kit gene encoding
a receptor tyrosine kinase [1-3]. The original NIH
(National Institutes of Health) classification of GIST
into four subgroups (very low, low, intermediate or high
risk) is based on tumour size and mitotic rate [1] and
supplemented by the addition of further parameters
[4-7]; (Additional file 1: Table S1). Tumour stage, as
well as tumour size, and mitotic rate are relevant mar-
kers for clinical outcome of GIST. The combination of
large tumour size and/or high mitotic rate is used to
identify high risk GIST which is associated with an
unfavourable prognosis [1,2]. The identification of genes
and gene products correlating with prognosis might
have therapeutic implications for further differentiation
of high risk GIST in the adjuvant setting. While surgery
remains the only curative treatment for GIST, small
molecule inhibitors like Imatinib targeting KIT and
PDGFR are used as the standard first-line treatment in
advanced disease [3,8]. At present, the use of Imatinib
in adjuvant treatment is controversial. The suggestion
by De Matteo and co-workers generally to use Imanitib
in adjuvant therapy of high risk GIST [9,10], has led to
pressing demands to introduce additional parameters
that help to stratify patients within the high risk GIST
group for additional adjuvant therapy concepts [9,10].
Genes involved in cell-cycle regulation, such as cyclins
and cyclin-dependent kinases (CDKs), are among such
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any medium, provided the original work is properly cited.potential markers [11,12]. The impact of deregulation in
regard to members of the cyclin-CDK-system on
tumourigenesis/tumour progression of GIST has only
been evaluated in a few studies [13-15]. There is evi-
dence that a low expression of p27KIP1 (CDKN1B, a
cyclin-dependent-kinase-inhibitor) is associated with
reduced progression-free survival [16-18]. Furthermore,
expression of cyclin A, cyclin B, cyclin D1 and cyclin E
seems to be associated with high risk grading but not
with clinical outcome [17,19,20]. At present there are no
data available regarding the role of cyclin H expression
in the progression of GIST. Cyclin H plays a key role in
cell cycle regulation by modulating the activity of CDK7
which phosphorylates CDK1, 2, 4 and 6 [21].
In this study, we investigated the expression pattern of
cyclin H in a single-centre population of 95 GIST and
evaluated its prognostic value, since our gene expression
analysis in normal and tumour tissue of a high-risk
GIST patient revealed a 10 fold upregulation of cyclin H
in tumour tissue.
Methods
Human tissue
Medical records as well as paraffin-embedded and fro-
zen specimens of 95 gastrointestinal stromal tumours
were included in the study. The clinocopathological fea-
tures are outlined in Table 1. Informed consent was
obtained from all patients. The study was performed
with the permission of the independent local ethics
committee of the University of Ulm (No. 90/2006
MuZGi).
Quantification and detection of Cyclin H mRNA
In a pilot study, total RNA was isolated from frozen
normal jejunal tissue and from a clinically very aggres-
sive tumour relapse which occurred 1.91 years after the
initial diagnosis of a jejunal high risk GIST in a 53-year
old female patient (clinical data: age at primary tumour
diagnosis: 51 years, features of the primary tumour: size:
9.5 cm, MR: 47 per 50 HPFs; Fletcher classification:
high risk of malignancy, no Imatinib treatment prior to
resection) using the RNAeasy Kit (Qiagen, Germany).
Total RNA (2 μg) was reversely transcribed into com-
plementary DNA using the RT
2 First Strand Kit (Super-
Array Bioscience Corp., USA). Gene profiling was done
as described by the manufacturer using the RT
2 profiler
PCR array for the human p53 signalling pathway (84
genes, SuperArray Bioscience Corp., USA). For CCNH
(gene encoding cyclin H), housekeeping gene HPRT1
(hypoxanthine Phosphoribosyltransferase 1) was used for
normalisation. The reactions were carried out in a 7500
Fast Real-Time PCR System (Applied Biosystems, USA).
The results were analysed with the 7500 Fast System
SDS Software 1.4 (Applied Biosystems, USA).
Histological evaluation
Original haematoxylin and eosin-stained tumour sec-
tions were used to evaluate cell type features and to
determine the mitotic rate in 50 high power fields (HPF,
magnification: 40×). GISTs were classified according to
Fletcher et al. [1] - (see Table 1). Additional risk estima-
tion was performed for all tumours according to the
classifications suggested by Miettinen et al. [7], Hornick
et al. [4] and Joensuu [6].
Table 1 Clinicopathologic Features
Initial symptoms (multiple mentions
possible)
n% o f
90
No clinical symptoms 25 28%
Pain 33 37%
GI bleeding 25 28%
Anemia 6 7%
Localization of primary tumour n %o f
95
Stomach 58 61%
Small bowel 29 31%
Jejunum 9 9%
Ileum 17 18%
Duodenum 3 3%
Colon 1 1%
Esophagus 2 2%
Others (EGIST, etc.) 5 5%
Second neoplasias n %o f
95
Total 30 32%
n %o f
30
Colorectal cancer 5 17%
Prostate cancer 4 13%
Breast cancer 3 10%
Gastric cancer 3 10%
Myometrial or cervical cancer 2 7%
Renal or urothelian cancer 2 7%
Pancreatic cancer 1 3%
Others 10 33%
Histomorphology n %o f
92
Spindle cell GIST 80 87%
Epithelioid/Mixed pattern 12 13%
Mixed pattern 11 12%
Epithelioid 1 1%
Risk of Malignancy (Fletcher et al.) n (sto/smbo/
ot)
n %o f
93
High risk 21/13/5 39 42%
Intermediate risk 13/5/1 19 20%
Low risk 14/7/0 21 23%
Very low risk 8/4/2 14 15%
sto = stomach, smbo = small bowel, ot = others
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For immunohistochemical analysis the following antibo-
dies were used: anti cyclin H (ab54903, monoclonal,
dilution 1:100, abcam, GB), anti KIT (CD117, C-KIT,
polyclonal, dilution 1:200, Dako, Glostrup Denmark),
anti smooth muscle actin (dilution 1:400, clone 1A4,
Dako), anti CD34 (dilution 1:100, clone QBEND10,
Dako), anti desmin (D33, monoclonal, 1:10, Linaris,
Germany), anti vimentin (Vim3B4, 1:300, Dako), anti
N S E( B B C / N C / V I - H 1 4 ;p o l y c l o n a l ,1 : 5 0 0 ,D a k o ) ,a n t i
S100 (polyclonal, 1:1000, Dako), anti Ki-67 (clone Mib-
1; dilution 1:200, Dako).
In brief, deparaffinised and re-hydrated tissue sections
(3 μm) were pretreated in a microwave in CitraPlus solu-
tion (Biogenex, USA; 2 minutes on 450 watt then on
80 watt for 20 minutes). After blocking the endogenous
peroxidase activity (peroxidase blocking agent, Dako,
Denmark), the sections were incubated with the mono-
clonal mouse anti cyclin H antibody followed by incuba-
tion with anti-mouse immunoglobulins conjugated with
peroxidase-labeled dextran polymers (N-Histofine,
Nichirei Corporation, Japan). Staining was detected with
3, 3'- diaminobenzidine (liquid DAB +, Dako, Denmark)
as chromogen and counterstained with hematoxylin
before being cover slipped. Cyclin H positivity was
defined as positive staining of ≥10% of the tumour cell
nuclei according to the modified classifications of Bondi
et al. and Kayaselcuk et al. [22,23]. Assessment was done
by estimating the rate of positive cells in 10 consecutive
fields of view (magnification: 20×) and calculation of the
arithmetic mean value of two independent reviewers
(TFEB, KK). Results of routine immunhistochemical
diagnostics such as expression of CD34, smooth muscle
actin, desmin, vimentin and NSE were included in statis-
tical analysis.
Statistical analysis
For investigation of the obtained data, an exploratory
data analysis was performed using SPSS 16 (SPSS Inc.,
USA) and Excel 2007 (Microsoft Corporation, USA). All
criteria were rated equally important, without adjust-
ment of p-values for multiple testing. Tumour size,
m i t o t i cr a t ea n da g ew e r ec o n s i d e r e dt ob ec o n t i n u o u s
variables, while others, such as positivity for immunohis-
tochemical markers, initial symptoms and sex, are trea-
ted as categorical variables.
To analyse hypotheses regarding the independence of
variables, a contingency table was created and either a
chi-square test (X
2), or (if one or more cells contain less
than 5 respondents) Fisher’s exact test was performed.
Testing was always done two-sided. For statistical analy-
sis of timeline-dependent parameters such as disease-
specific survival, a Kaplan-Meier estimation was created
and significance was tested using log-rank test. For the
calculation of disease-specific-survival (DSS), non GIST-
related death-events were censored. P-values < 0.05
were considered statistically significant (a = 0.05). No
correction for multiple testing was done.
Results
A single-centre population of ninety five patients with a
mean age of 64.3 years (median 66.9 ± 13.5) ranging
from 17 to 94 years and a male/female ratio of 42/53
(44% men, 56% women) underwent surgical resection
for a GIST via laparotomy (except one: only biopsy, see
below). Clinical manifestations, pathological findings,
treatment options, and clinical outcome were evaluated,
and statistical analyses were carried out with regard to a
potential predictive value of cyclin H.
Major clinical symptoms, tumour location, histomor-
phology, immunohistology and risk classification are
summarised in Table 1 and 2. Tumour size varied
between 0.4 and 30.0 centimetres (mean 7.4 ± 5.6) and
the mitotic rate per 50 HPF ranged from 0 to 116
(mean 10.8 ± 21). No major differences were obtained
by using alternative risk estimations (risk of progressive
disease, risk of tumour progression, risk category,
according to Miettinen et al. [7], Hornick et al. [4] and
Joensuu [6]. All four classification scales did significantly
differentiate between high risk and non-high risk GIST
(p < 0.001); Table 3.
Dependent on the primary tumour site and the extent
of tumour growth, final resection state was R0 in 83
(88%), R2 in 7 (8%) and R1 in 4 (4%) of 94 patients; one
94-year-old patient with a huge gastric GIST was not
resected and only biopsies were performed due to a
coexisting metastatic obstructive colonic cancer. 16
out of 27 patients who had tumour recurrence and/or
metastases were treated with imatinib (200-800 mg/d)
in addition to surgery. Of these 15 patients, 8 (50%)
achieved stable disease, 4 (25%) attained a partial remis-
sion and 4 (25%) had tumour progression. Imatinib
did not lead to a complete remission in any of our
patients.
Table 2 Immunohistochemical Results in GIST
Immunohistochemistry Positive, n (%) Negative, n (%) Total, n
c-kit (CD117) 92 (98%) 2 (2%) 94
cyclin H 23 (24%) 72 (76%) 95
CD34 63 (85%) 11 (15%) 74
smooth muscle actin 11 (17%) 53 (83%) 64
desmin 4 (9%) 43 (91%) 47
vimentin 32 (100%) 0 (0%) 32
NSE 6 (55%) 5 (45%) 11
S100 0 (0%) 55 (100%) 55
Two c-kit negative GIST turned to be PDGFRa positive, confirmed as GIST by
mutational analysis
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Median follow-up time of the surviving patients was
5.37 years (64.39 months) (mean 6 years, range 0.4 to
20.2 years). At the time of diagnosis, 15% (n = 14) of all
GIST patients showed metastatic disease. 16% (n = 15)
of the patients died due to GIST-related causes (overall
survival 69% (n = 66)) and the rate of patients with
metastases or tumour recurrence increased to 27% (n =
26) during the time of observation. Disease-specific 1-,
3-, and 5-year survival probability (DSS) was 96%, 87%,
and 84%. Respectively, disease-free survival (DFS) was
80%, 76% and 72%. The median disease-free interval
after primary diagnosis of patients with primary unifocal
disease and later developed metastases or tumour recur-
rence was 2.1 years (25 months), mean 2.6 years (31.5
months), range 0.5 to 6.1 years (5.6 to 73 months).
Interestingly, 32% (n = 30) of the patients exhibited
additional malignant neoplasms. Concurrent benign
neoplasias were found in 17% (n = 16). Results of the
survival analysis are summarised in Tables 3, 4, 5 and in
Figure 1, 2, 3, 4, 5.
Cyclin H expression and clinical outcome (see also
Table 3, 4, 5)
Quantification of cyclin H expression by Real time PCR
in normal intestinal tissue and in a relapse of a jejunal
high risk GIST indicated that cyclin H transcription is
increased by 10 fold in the tumour tissue. Based on this
high transcription level of cyclin H in one GIST, we
analysed cyclin H expression at a protein level in the
tumour tissue of the same patient. A high nuclear stain-
ing of cyclin H was detected. Consequently, immunohis-
tochemical analysis of cyclin H expression in the
tumour tissue of 95 GIST patients was undertaken and
revealed nuclear positivity of cyclin H in 24% (n = 23)
(cut-off value of ≥10% reactive cells) (Figure 6). In the
majority of these tumours the intensity was moderate
positive (19/23) and only 5 tumours showed a very
Table 3 P values regarding different parameters in GIST
Independent Variables TRD DSS DFS Met/Rec Count
Tests: c2/Fisher Exact Log-Rank Log-Rank c2/Fisher Exact (n)
Sex 0.180 0.226 0.647 0.626 95
Localization (stomach vs. small bowel) 0.671 0.618 0.433 0.611 87
Tumour size (≥ 5 cm vs. <5 cm) 0.005 0.008 <0.001 <0.001 92
Tumour size (≥ 10 cm vs. <10 cm) <0.001 <0.001 <0.001 <0.001 92
Mitotic rate (≥ 5/50 HPF vs. <5/50 HPF) 0.001 0.001 <0.001 <0.001 90
Mitotic rate (≥ 10/50 HPF vs. <10/50 HPF) <0.001 <0.001 <0.001 <0.001 90
Histomorphology (spindle vs. not) 0.103 0.099 0.217 0.187 92
Fletcher (high vs. non-high) <0.001 <0.001 <0.001 <0.001 93
Joensuu (high vs. non-high) <0.001 <0.001 <0.001 <0.001 89
Miettinen (high vs. non-high) 0.001 <0.001 <0.001 <0.001 86
Hornick (high vs. non-high) <0.001 <0.001 <0.001 <0.001 90
Primary tumour state (unifocal vs. not) <0.001 <0.001 <0.001 – 93
CD34 (pos vs. neg) 0.680 0.511 0.744 1.000 74
Aktin (pos vs. neg) 1.000 0.818 0.844 1.000 64
Desmin (pos vs. neg) 1.000 0.930 0.602 1.000 47
Cyclin H (pos vs. neg) 0.369 0.189 0.692 0.806 95
Fletcher (high vs. non-high) <0.001 <0.001 <0.001 <0.001 93
Cyclin H (pos vs. neg, only high-risk) 0.435 0.038 0.552 1.000 39
Cyclin H (pos high risk vs rest) 0.004 <0.001 0.001 0.011 95
Joensuu (high vs. non-high) <0.001 <0.001 <0.001 <0.001 89
Cyclin H (pos vs. neg, only high-risk) 0.281 0.009 0.330 0.730 40
Cyclin H (pos. high-risk vs. rest) 0.004 <0.001 <0.001 0.007 89
Miettinen (high vs. non-high) 0.001 <0.001 <0.001 <0.001 86
Cyclin H (pos vs. neg, only high-risk) 0.681 0.050 0.967 0.696 32
Cyclin H (pos. high-risk vs rest) 0.035 <0.001 0.012 0.053 86
Hornick (high vs. non-high) <0.001 <0.001 <0.001 <0.001 90
Cyclin H (pos vs. neg, only high-risk) 0.306 0.020 0.502 1.000 36
Cyclin H (pos. high-risk vs. rest) 0.003 <0.001 0.001 0.007 90
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classified as low risk,1a svery low risk and 1 as high
risk GIST. Further interpretation of strongly positive or
moderate positive cannot be assessed because of the
limited number of cases. Analysis of the relationship
between nuclear cyclin H positivity and risk of malig-
nancy according to Fletcher and co-workers [1] revealed
that high risk GIST tumours are 3 times more fre-
quently cyclin H positive than very-low risk GIST (p =
0.176). The disease-specific survival (DSS) of cyclin H
positive GIST-patients after 1, 3 and 5 years is approxi-
mately 10% below the cyclin H negative cohort
(log-rank test, p = 0.189) and within the cyclin H posi-
tive GIST patients the disease specific mortality rate is
22% compared to 14% in patients with cyclin H negative
GIST (p = 0.369); Table 3. Of the 23 tumours stained
positive for Cyclin H the distribution with regard to the
different risk categories was as follows: 11 of 39 high
risk GIST (28%), 4 of 19 intermediate risk (21%) and 8
of 35 low or very low risk GIST (23%). With focus on
the high risk group, cyclin H positivity is significantly
related to reduction of disease-specific survival (log-
r a n k :p=0 . 0 3 8 ;s e eT a b l e s3& 5 ;F i g u r e3 ) .I np a t i e n t s
who were affected by tumour recurrence or metastases,
Table 4 Results of the Survival Analysis in GIST
Non-Disease-specific 1-year 3-year 5-year
Overall survival 91% 79% 71%
1-year DSS (%) 3-year DSS (%) 5-year DSS (%) 1-year DFS (%) 3-year DFS (%) 5-year DFS (%)
Whole cohort
Survival 96 87 84 80 76 72
Risk of malignancy according to Fletcher et al. 2002 [1]
Very low 100 100 100 100 100 100
Low 100 95 95 95 95 95
Intermediate 100 100 100 100 100 100
High 89 71 65 53 44 38
Non-high 100 98 98 98 98 98
Cyclin H
Positive 90 80 72 78 67 67
Negative 97 89 87 80 79 73
Other criteria
Prim-local 100 97 94 95 90 85
Prim-metastasis 72 33 33 –––
Met: any time 84 56 46 27 19 8
R0 resection 97 94 90 88 86 85
R1/2 resection 83 40 40 33 25 25
DSS = disease specific survival; DSF = disease free survival
Table 5 Survival and p-values with focus on subgroups of GIST regarding Cyclin H expression
High-Risk DSS DFS
Cyclin H positive
(n = 11)
negative
(n = 28)
all
(n = 39)
positive
(n = 11)
negative
(n = 28)
all
(n = 39)
1-year probability (%) 75 93 89 51 53 52
3-year probability (%) 50 77 71 26 49 44
5-year probability (%) 33 73 65 26 41 38
Log-Rank Test (p) p = 0.038 p = 0.522
Tumour Recurrence or Metastases DSS DFS
Cyclin H positive
(n = 7)
negative
(n = 20)
all
(n = 27)
positive
(n = 7)
negative
(n = 20)
all
(n = 27)
1-year probability (%) 67 90 84.9 27 30 30
3-year probability (%) 33 64 57.0 0 25 19
5-year probability (%) 0 58 47.5 0 10 7
Log-Rank Test (p) p = 0.016 p = 0.362
(results of immunostaining)
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Page 5 of 13Figure 1 Disease specific survival - high versus non-high. Disease specific survival (DSS) of the different risk of malignancy groups according
to Fletcher; p < 0.001 (high versus non-high).
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Page 6 of 13Figure 2 Disease free survival - high versus non-high. Disease free survival (DFS) of the different risk of malignancy groups according to
Fletcher; p < 0.001 (high versus non-high).
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Page 7 of 13Figure 3 DSS according to Cyclin H expression in high risk GIST. DSS in comparison of Cyclin H staining in high risk GIST; positive versus
negative (p = 0.038).
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Page 8 of 13Figure 4 Cyclin H expression and high risk classification as predictor (DSS). Comparison of DSS of all cyclin H positive high risk GIST versus
all cyclin H negative high risk GIST as well as all other GIST classified as intermediate, low and very low summarised as control group (p < 0.001).
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Page 9 of 13Figure 5 Cyclin H expression and high risk classification as predictor (DFS). Comparison of DFS of all cyclin H positive high risk GIST versus
all cyclin H negative high risk GIST as well as all other GIST classified as intermediate, low and very low summarised as control group (p < 0.001).
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Page 10 of 13cyclin H positivity indicated a significantly lower dis-
ease-specific survival (e.g. 33.3% vs. 64.2% after 3 years,
p = 0.016 log-rank test, see Table 5). The combination
of cyclin H positivity and high risk GIST showed the
strongest predictive p-value for poor disease-free as well
as disease-specific survival (p = 0.001 and p < 0.001,
log-rank test; cyclin H positive high risk GIST in com-
parison with the rest of the whole population; see Table
3 and Figure 5 &6).
No association was found between cyclin H status and
localisation of the primary tumour (p = 0.471), sex (p =
0.935), and routine immunohistochemical markers such
as CD34 (p = 1.000), smooth muscle actin (p = 0.479),
desmin (p = 0.564) and Ki-67 (p = 0.227); Table 3. In
multivariate analyses, no statistically relevant related fac-
tors could be detected.
Discussion
The aim of the present study was to evaluate the prog-
nostic value of cyclin H expression in GIST. To this
end, the expression of cyclin H was analysed at the
mRNA (single case pilot analysis) and consecutively at a
protein level of the whole cohort. The cyclin H immu-
nostaining pattern of tumours of 95 patients with GIST
was characterised and correlated to clinicopathologic
features and clinical outcome.
Due to the absence of reliable genetic or immunohisto-
chemical predictors, tumour size and mitotic rate are still
the determining NIH criteria for risk estimation in GIST
[1]. Although the classification distinguishes the tumours
using a four-point scale (very low, low, intermediate and
high risk of malignancy), this scale is only useful to
differentiate between high-risk and non-high-risk GIST.
High risk classification according to Fletcher et al. [1] is a
reliable predictor for the development of metastases or
tumour relapse since 85-97% of the affected patients ori-
ginate from the high risk group. No major differences
were found by using alternative risk classification scales
according to Miettinen et al., Hornick et al. and Joensuu
[4,6,7]. In contrast the high risk group itself remains
inhomogeneous based on the period of long-term dis-
ease-specific and disease-free survival of GIST patients
even without adjuvant treatment (DSS 65%, DFS 38%
after 5 years in our study cohort; Table 5; Figure 1 &2).
These findings are in line with previous published data
and comments highlighting differences up to 100%
within this group [9]. In the light of adverse drug effects,
the development of secondary resistance to commercial
available and broadely used tyrosine kinase inhibitor
(TKI) in molecular target based therapy concepts and
high annual treatment costs (40,000-80,000 €/year)
[3,9,24] it seems mandatory to detect prognostic factors
helping to use adjuvant therapy more selectively by iden-
tifying patients with a “very-high” risk within the high
risk group particularly after an R0 resection.
Quantification of cyclin H mRNA revealed a 10.2 fold
increased transcription of cyclin H in a high risk jejunal
GIST compared to normal tissue, suggesting an impor-
tant role of cyclin H and the cyclin-CDK-system in
GIST pathogenesis. By immunohistochemical analysis of
cyclin H expression in 95 tumour specimens of a single
centre population we found a high expression of cyclin
H( ≥ 10% reactive cells) in 24% of the tumours, which
correlated well with the risk of malignancy (p = 0.176).
Figure 6 Expression of cyclin H in gastrointestinal stromal tumours. Serial sections of gastrointestinal stromal tumours (GISTs) were
immunostained using the anti cyclin H specific monoclonal antibody ab54903. A: negative staining; B: GIST showing a fraction of positively
stained cell nuclei; C: positivity of almost all cells with strong nuclear and faint cytoplasmic staining.
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study there is a tendency for a poor prognosis, although
there was no statistical significance (p = 0.692 for DFS
and p = 0.189 for DSS). In patients with high risk GIST
the expression of cyclin H was highly predictive for the
reduction of DSS (p = 0.038). Accordingly, cyclin H
expression differentiated high risk and “very-high risk”
GIST with regard to disease-specific mortality and
might be a valuable tool for further treatment decisions.
Moreover, with regard to the whole population, the
combination of cyclin H positivity and high risk classifi-
cation according to Fletcher was strongly predictive of a
poor DFS as well as DSS (p = 0.001 and p < 0.001) [1].
Additionally, in patients with tumour recurrence and/or
metastases, cyclin H positivity was significantly asso-
ciated with reduced disease-specific survival (p = 0.016)
regardless of risk-classification.
Although the predictive value of Cyclin H is limited
with regard to the whole population, our results suggest
for the first time a predictive value of cyclin H expres-
sion in high risk GIST patients, underlining the impor-
tance of the cyclin-CDK system for GIST pathogenesis.
Therewith, our data strengthen previous reports on the
predictive value of cyclin A, cyclin B, cyclin D1, cyclin
E, cdc2, p27 and p21 [16-20,25-27]. However, immuno-
histochemical positivity of cyclin A, cyclin B, cyclin D1,
cyclin E and cdc2 [17,19,20] or the loss of cyclin kinase
inhibitors p27 and p21 [16-18,25-27] has only been
shown to be associated with high risk grading in GIST,
while investigations in regard to clinical outcome are
missing. In contrast, our data show a significant correla-
tion of Cyclin H expression with reduced DSS in high
risk GIST and in patients with metastases or tumour
recurrence.
The efforts to identify parameters that clearly correlate
with the clinical outcome of GIST are not restricted to
the cyclin-CDK-system. Similarly, the prognostic value
of various other factors, such as p53, p16, p21, pRb,
E2F1, p27KIP1, Mdm2, Bcl-2 and Bax is not yet entirely
clarified. Although changes in their expression have
been evaluated in regard to risk ranking, in most cases
their correlation with the clinical outcome (DSF, DSS,
PFS) has not been validated in detail. Furthermore, the
conclusions drawn are still in some cases contradictory
[3,17,18,28,29]. Moreover, data relating to the prognostic
value of the mutational status are still under debate
[30-34]. Altogether, this suggests that one factor does
not satisfy the multi-factorial and multidimensional
complexity of tumourigenesis and tumour progression
of GIST. The identification of factors with a potential
prognostic value, as here described for cyclin H, is an
important prerequisite for multi-factorial analyses.
Simultaneous analysis of cyclin H and a previously
investigated factor, p16 [28], within an intersection
sub-cohort revealed that the combined positivity of both
parameters indicates poor outcome of GIST, irrespective
of the mitotic rate or tumour size (p = 0.039) (Addi-
tional file 2: Table S2 & S3 and Figure S1). After one
year, 50% of the patients with cyclin H- and p16-positive
high risk GIST died and none of these patients was
tumour free in comparison to 98% survivors and 83%
tumour-free patients in the control group. These find-
ings indicate the necessity of multi-factorial follow-up
studies (in larger series) for the future.
Conclusions
In conclusion, conventional risk estimations including
tumour size, mitotic rate and tumour location are useful
to differentiate high risk and non-high risk GIST. The
combination of positivity for cyclin H and high risk clas-
sification predicts highly significant poor prognosis in
GIST. Also in patients with recurrence or metastases,
the expression of cyclin H is the only relevant clinical
predictor. Therefore, protein expression of cyclin H may
allow subclassification of “very-high risk” (cyclin H-posi-
tive high risk GIST) from high risk GIST. Whether
cyclin H alone or in combination with any other factor
will be an indicator for the necessity of adjuvant treat-
ment of R0-resected high risk GIST with a tyrosine
kinase inhibitor remains to be further investigated.
Additional material
Additional file 1: Table S1. Table 1: Suggested risk classifications
Additional file 2: Table S2 & S3 and Figure S1. Table S2: Combined
Cyclin H and p16 positivity - Results of the Survival Analysis Table S3: P
values for Combined Cyclin H and p16 positivity Figure S1: Disease
specific survival in high-risk GIST with combined positivity for cyclin H
and p16 (p < 0.001).
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